Form 4: Elevation Oncology's Chief Medical Officer, Valerie Jansen, Reports Stock Transactions

Valerie Jansen, Chief Medical Officer of Elevation Oncology, reports the vesting of restricted stock units and associated tax withholding, along with the grant of stock options.

Summary

• Valerie Jansen, the Chief Medical Officer of Elevation Oncology, filed a Form 4 detailing changes in her beneficial ownership of the company's stock.
• On February 15, 2025, 17,500 restricted stock units (RSUs) vested, resulting in the acquisition of 17,500 shares of common stock.
• Also on February 15, 2025, 5,189 shares were disposed of to cover tax obligations at a price of $0.6717 per share.
• Following these transactions, Jansen directly owns 12,311 shares of Elevation Oncology common stock.
• Jansen was also granted a stock option to purchase 275,000 shares of common stock at an exercise price of $0.6717, which vests over time.
• The stock option vests as to 25% of the total shares on February 15, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
• 25% of the RSUs vested on February 15, 2025, and the remainder will vest as to 1/16 of the total RSUs quarterly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to equity compensation. The vesting of RSUs and granting of stock options are generally positive signals, but the tax withholding is a neutral event.

Positives

• The grant of stock options to the Chief Medical Officer aligns her interests with those of the shareholders, incentivizing her to improve the company's performance.
• The vesting of RSUs indicates that the officer has met certain performance or time-based milestones.

Negatives

• The disposal of shares to cover tax obligations, while common, slightly reduces the officer's stake in the company.

Risks

• The value of the stock options is dependent on the future performance of Elevation Oncology's stock price.
• If the stock price does not increase above the exercise price of $0.6717, the options may not be valuable.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the vesting schedule of the stock options and RSUs suggests a continued commitment from the Chief Medical Officer.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Comparison to Industry Standards

• Equity compensation is a standard practice in the biotechnology industry to attract and retain talent.
• The vesting schedules for the stock options and RSUs are typical for executive compensation packages.
• Comparing the size of the equity grants to those of peer companies would provide further context on the competitiveness of Elevation Oncology's compensation practices.

Stakeholder Impact

• Shareholders may view the equity compensation as aligning management's interests with their own.
• Employees may be motivated by the potential for equity ownership.

Key Dates